NNZ-2591, also named ercanetide, is a tiny ring-shaped dipeptide. It was built as a stable copy of cyclic glycine-proline, a molecule linked to insulin-like growth factor 1 (IGF-1). Neuren Pharmaceuticals is testing it in rare childhood neurodevelopmental disorders. This guide covers its structure, proposed mechanism, trials, side effects and status. Sources were checked on November 17, 2026.
Quick answer: NNZ-2591 is an investigational drug, not an approved medicine. Neuren reports FDA Fast Track designation for Phelan-McDermid, Pitt Hopkins and Angelman syndromes. Its phase 2 results come from open-label studies without a placebo group. A randomized phase 3 trial in Phelan-McDermid syndrome began in November 2025.
Vitrapep does not sell NNZ-2591; this page is a reference summary of published research and regulatory information.
What is NNZ-2591?
NNZ-2591 is cyclo-L-glycyl-L-2-allylproline. In plain terms, a glycine and a proline carrying an extra allyl group are joined head to tail in a ring. Chemists call this ring a diketopiperazine. PubChem lists the formula C10H14N2O2 and a molecular weight of 194.23 g/mol. It also lists the nonproprietary name ercanetide (PubChem CID 11735696).
It counts as a peptide in the smallest sense: two amino acid units linked by peptide bonds, closed into a ring. Its parent molecule, cyclic glycine-proline (cGP), is reviewed in the literature as a cyclic dipeptide (Hu et al., 2024). Our guide to types of peptides covers linear and cyclic forms.
A 2009 review describes cGP as an endogenous diketopiperazine that “may be derived from GPE.” GPE is a three-amino-acid fragment cleaved from the start of IGF-1 (Guan & Gluckman, 2009). The same review calls NNZ-2591 “highly enzymatic resistant and centrally accessible.”
NNZ-2591: key facts
| Fact | Detail |
|---|---|
| Structure type | Cyclic dipeptide (diketopiperazine) of glycine and 2-allylproline |
| Class | Synthetic analog of cyclic glycine-proline, an IGF-1-related molecule |
| Molecular formula | C10H14N2O2 |
| Molecular weight | 194.23 g/mol |
| Development stage | Phase 3 in Phelan-McDermid syndrome, recruiting since November 2025 |
| Sponsor or developer | Neuren Pharmaceuticals |
How does NNZ-2591 work?
The proposed mechanism centers on IGF-1. The phase 2 trial authors describe NNZ-2591 as “a synthetic analog of the IGF-1 metabolite cyclic glycine-proline.” They write that cGP “regulates IGF-1 bioavailability and homeostasis through an autoregulatory mechanism.” Their hypothesis is that NNZ-2591 mimics that action (Neumeyer et al., 2025). As support, they cite a Shank3-deficient mouse model in which IGF-1 treatment led to improvements.
Earlier animal work tested brain protection. In adult rats with hypoxic-ischemic brain injury, NNZ-2591 reduced brain damage and improved somatosensory-motor function. It was stable in plasma and crossed the blood-brain barrier (Guan et al., 2007). These are animal data, not human results.
Phelan-McDermid syndrome is caused by a deletion or other change in the 22q13 region of chromosome 22, which includes the SHANK3 gene. Neuren notes that the SHANK3 protein supports the structure of synapses between neurons (Neuren, 2025).
What is NNZ-2591 being studied for?
NNZ-2591 is not approved by the FDA for any use. Neuren Pharmaceuticals sponsors every registered trial. ClinicalTrials.gov lists these patient studies:
- Phelan-McDermid syndrome: phase 2, open-label, 18 children, completed 2023 (NCT05025241);
- Pitt Hopkins syndrome: phase 2, open-label, 28 participants, completed 2024 (NCT05025332);
- Angelman syndrome: phase 2, open-label, 17 participants, completed 2024 (NCT05011851);
- Phelan-McDermid syndrome: phase 3, randomized, placebo-controlled, about 160 children aged 3 to 12, recruiting (NCT07281079); and
- Phelan-McDermid syndrome: phase 3 open-label extension, about 180 children, recruiting (NCT07593391).
A planned Prader-Willi syndrome study was withdrawn before anyone enrolled. Neuren calls its phase 3 trial, Koala, “the first ever Phase 3 clinical trial for PMS.” The company says it reached alignment with the FDA that this single trial’s design and endpoints could support a New Drug Application (Neuren, 2025).
What did the key trials show?
Phelan-McDermid syndrome, phase 2. This is the only peer-reviewed clinical result we found. It was a multisite, single-group, open-label study in 18 children aged 3 to 12. Its primary goals were safety and pharmacokinetics. Ten of 14 secondary efficacy assessments improved significantly from baseline at week 13 (Neumeyer et al., 2025).
On the clinician-rated, syndrome-specific Clinical Global Impression of Improvement, the mean score was 2.4 (p < 0.0001). Clinicians rated 16 of 18 children as improved. On the caregiver version, 15 of 18 were rated improved (p = 0.0003). Without a placebo group, the study could not separate drug effects from other causes of change. Neuren funded the study.
Pitt Hopkins and Angelman syndromes. Neuren describes its phase 2 results in both conditions as positive (Neuren, 2025). We found no peer-reviewed paper or posted registry results for either study.
Phase 3. The Koala trial compares NNZ-2591 with placebo under quadruple masking. Its primary outcome is the Phelan-McDermid Syndrome Assessment of Change overall score at week 13 (NCT07281079). No results have been posted.
What side effects have studies reported?
In the phase 2 Phelan-McDermid trial, 17 of 18 children (94.4%) had at least one treatment-emergent adverse event. Most were mild to moderate. The most common were:
- psychomotor hyperactivity: 4 children (22.2%); and
- COVID-19, decreased appetite, fever and sleepiness: 3 children each (16.7%).
There was one serious event, gastroenteritis after treatment ended, judged unrelated to the drug. Three children stopped early: two because of COVID-19 and one because of seizures. Investigators judged all three unrelated. One severe episode of hyperactivity was judged possibly related and resolved the next day (Neumeyer et al., 2025).
What is NNZ-2591’s regulatory status, and how is it used in research?
NNZ-2591 is an investigational drug in the United States. On October 20, 2025, Neuren announced FDA Fast Track designation for Phelan-McDermid syndrome. The release says Fast Track also covers Pitt Hopkins and Angelman syndromes. It adds that each of the three programs holds orphan drug designation in the US and the EU (Neuren, 2025). Fast Track and orphan designations support development; neither is an approval.
Before the clinical program, NNZ-2591 was studied mainly in rats. Published models include hypoxic-ischemic brain injury and scopolamine-induced memory impairment. In the memory study, NNZ-2591 improved retention but did not reverse the learning deficit (Guan et al., 2010). Neuren’s first product, trofinetide, is FDA-approved for Rett syndrome as DAYBUE. For how investigational compounds differ from approved drugs, see research use only, explained.
Frequently asked questions about NNZ-2591
Is NNZ-2591 a peptide?
Yes, in the smallest sense. It is a cyclic dipeptide, also called a diketopiperazine, made from glycine and a modified proline.
What is ercanetide?
Ercanetide is the nonproprietary name PubChem lists for NNZ-2591.
Is NNZ-2591 FDA approved?
No. It is in phase 3 testing for Phelan-McDermid syndrome. Neuren reports Fast Track and orphan designations, which are not approvals.
What did the phase 2 trial in Phelan-McDermid syndrome show?
It reported improvement from baseline in 10 of 14 measures in 18 children. The study had no placebo group.
How is NNZ-2591 related to trofinetide?
Both come from Neuren. Trofinetide is approved for Rett syndrome as DAYBUE, while NNZ-2591 is still in trials.
What to know now
- Structure: cyclic dipeptide of glycine and 2-allylproline; 194.23 g/mol.
- Origin: synthetic analog of cyclic glycine-proline, an IGF-1-related molecule.
- Status: not FDA-approved; Fast Track for three rare syndromes, per Neuren.
- Evidence: open-label phase 2 in 18 children; 10 of 14 measures improved from baseline.
- Safety: most adverse events mild to moderate; hyperactivity most common.
- Next: placebo-controlled phase 3 (Koala) recruiting about 160 children.
What we’re watching
Results from the Koala phase 3 trial, with primary completion estimated for October 2027 on ClinicalTrials.gov. Peer-reviewed reports of the Pitt Hopkins and Angelman phase 2 studies. Related guides: trofinetide, davunetide and cerebrolysin.